EPO and neoplasm: In DLD-1 xenografts receiving Epo+LFM-A13, differences in tumor growth between the first and the zero week as well as the second and the zero week were significantly smaller compared with the control (p < 0.05, p < 0.05, respectively, Figure 4a).